Homa-ir

Homa-ir has been studied in 2 papers since 2025: 1 observational study in people, 1 review; 2 in the past year. The newest paper, Jul 24, 2026: “Insulin Resistance Indices and Subclinical Left Ventricular Systolic Dysfunction in Adults: A Systematic Review and Meta-Analysis”.

Exposure

2 papers study it1 findingUpdated Jul 24, 2026

See all 2 papers on homa-ir

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Hazard ratios (HRs) of incident CRMM associated with each 1-standard deviation (SD) increase in FPG, 2hPG, insulin (natural log), and HOMA-IR (natural log) were 1.48 (95 % CI: 1.34-1.64)”

Nonlinear association between glycemic markers and incident cardio‑renal‑metabolic multimorbidity: two decades of follow‑up in the Tehran Lipid and Glucose StudyAmerican journal of preventive cardiology2025doi:10.1016/j.ajpc.2025.101353

1 lab in 1 country

Humans1

What is homa-ir linked with?

Studies link homa-ir with cardio-renal-metabolic multimorbidity.

Cardio-renal-metabolic multimorbidity

upin humans1HR 1.22

1 study

Homa-ir is linked with a higher risk of cardio-renal-metabolic multimorbidity in humans (per 1-standard deviation increase in natural log) (HR 1.22 (95% CI 1.01-1.47) per 1-SD increase in natural log).
“Hazard ratios (HRs) of incident CRMM associated with each 1-standard deviation (SD) increase in FPG, 2hPG, insulin (natural log), and HOMA-IR (natural log) were 1.48 (95 % CI: 1.34-1.64)”
Humansper 1-standard deviation increase in natural logmedian follow-up of 15.3 years
Nonlinear association between glycemic markers and incident cardio‑renal‑metabolic multimorbidity: two decades of follow‑up in the Tehran Lipid and Glucose Study
American journal of preventive cardiologyNov 19, 2025

More on Cardio-renal-metabolic multimorbidity